Expand all sections

Ozanimod

Extended indication RMS.
Therapeutic value No judgement

Product

Active substance Ozanimod
Domain Neurological disorders
Main indication Multiple sclerosis
Extended indication RMS.
Manufacturer celgene
Route of administration Oral
Therapeutical formulation Capsule
Budgetting framework Extramural (GVS)
Additional remarks Toedieningsvorm: naast een Capsule-vorm komt Ozanimod ook als vloeistof beschikbaar voor kinderen (bron EMA).

Registration

Registration route Centralised (EMA)
Submission date September 2018
Expected Registration July 2019
Orphan drug No

Therapeutic value

Therapeutic value No judgement
Frequency of administration 1 times a day
Dosage per administration 0,5-1 mg

Expected patient volume per year

Patient volume

400 - 800

Market share is generally not included unless otherwise stated.
Additional remarks Verwachting minder patiënten dan Ocrevus.

Expected cost per patient per year

References Prescribing Outlook 2017
Additional remarks Prescribing Outlook 2017: 'High cost drug.'

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.